Clinical reference Biomarker Directory
Back to directory

Beta-Galactosidase

Emerging

Beta-galactosidase (GLB1) deficiency causes GM1 gangliosidosis and Morquio syndrome type B, both rare lysosomal storage disorders.

Also known as GLB1 beta-gal acid beta-galactosidase
In plain language

This enzyme breaks down certain fatty substances in cells. Without enough of it, severe inherited conditions develop, ranging from a serious infant brain disease to a milder bone-affecting condition. There's no approved treatment yet, though gene therapy research is actively underway.

Biomarker & context

Beta-galactosidase, encoded by the GLB1 gene, is a lysosomal enzyme that breaks down specific glycolipids and glycoproteins; its deficiency causes rare, severe genetic storage disorders.

What it indicates

Deficiency causes GM1 gangliosidosis, a severe infantile neurodegenerative lysosomal storage disease, and, in a milder allelic form, Morquio syndrome type B, a distinct skeletal storage disorder.

Diagnosis & clinical testing

Diagnosed via enzyme activity assay in leukocytes or cultured skin fibroblasts, with genetic testing confirming the specific GLB1 mutation and helping distinguish the severe infantile form from milder, later-onset variants.

Guiding treatment

No enzyme replacement therapy is currently approved for GM1 gangliosidosis, though it's an active area of gene therapy research; management is primarily supportive, making early diagnosis important mainly for family genetic counseling and clinical trial eligibility.

Clinical significance

No approved enzyme replacement therapy yet exists, though gene therapy research is an active area for GM1 gangliosidosis.

References
  1. General genetics/metabolic disease reference literature on GLB1-related GM1 gangliosidosis and Morquio syndrome type B.